Ultragenyx Pharmaceutical RARE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$574.92M-1.0% | -$569M+6.3% | -$607M+14.2% | -$707.42M-55.8% | ||
| $35M-2.8% | $36M+38.5% | $26M+42.7% | $18.22M+37.6% | ||
| -$466M-12.6% | -$414M+12.8% | -$475M-24.8% | -$380.47M-12.3% | ||
| $6M-14.3% | $7M-84.1% | $44M-62.1% | $116.12M+58.9% | ||
| —— | —— | —— | -$291.65M— | ||
| $252M— | —— | $81M+145% | -$178.49M— | ||
| -$472M-12.1% | -$421M+18.9% | -$519M-4.5% | -$496.59M-20.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.